Chen Tanping, Luo Jing, Li Shuai, Li Xinyan, Wang Wenhao, Lu Wenlong, He Yandong, Xu Xiaolin
Shanghai Fengxian District Central Hospital, School of Medicine, Anhui University of Science and Technology, Shanghai, China.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., Shanghai, China.
Lipids Health Dis. 2025 Jun 20;24(1):219. doi: 10.1186/s12944-025-02640-4.
Pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) are considered to have protective effects on cardiovascular health. However, research on the relationship between C15:0 and C17:0 levels and hypertension remains limited. This cross-sectional study aims to investigate the association between serum levels of odd-chain fatty acids (C15:0 and C17:0) and prevalent hypertension.
Data from the 2011-2014 National Health and Nutrition Examination Survey (NHANES) were used for this study. Multiple logistic regression models, restricted cubic spline (RCS) analysis, saturation threshold effect analysis, and interaction effect tests were employed to analyze the relationship between serum C15:0 and C17:0 levels and prevalent hypertension.
A total of 4,775 participants (C15:0 analysis group) and 4,718 participants (C17:0 analysis group) were included in this study. The prevalence of hypertension in the two groups is 46.99% and 46.82%, respectively. To improve the distribution and comparability of the data, the primary analysis used the per mille of total fatty acids (C15:0‰ and C17:0‰). After adjusting for multiple confounders, both C15:0‰ and C17:0‰ levels were significantly inversely associated with the odds of prevalent hypertension. In the fully adjusted model, an increase in C15:0‰ and C17:0‰ levels was associated with a lower odds of prevalent hypertension (C15:0‰: OR = 0.78, 95% CI: 0.66-0.93, P = 0.0063; C17:0‰: OR = 0.77, 95% CI: 0.64-0.93, P = 0.0074). Further restricted cubic splines analysis showed a significant nonlinear relationship between C15:0‰ level and prevalent hypertension. Saturation threshold effect analysis revealed that when C15:0‰ level was below 1.5‰, the inverse association with the odds of prevalent hypertension was stronger (OR = 0.42, 95% CI: 0.23-0.77, P = 0.0052), while the relationship weakened when C15:0‰ level was above 1.5‰ (OR = 0.89, 95% CI: 0.74-1.07, P = 0.2158). Interaction effect tests indicated that, in the subgroup with C15:0‰ level ≥ 1.5‰, age modified the relationship between C15:0‰ level and prevalent hypertension. In the population aged ≥ 65 years, C15:0‰ level was inversely associated with the odds of prevalent hypertension (OR = 0.54, 95% CI: 0.36-0.79, P = 0.0384), while no significant association was observed in the population aged < 65 years (OR = 0.83, 95% CI: 0.68-1.02, P = 0.1032).
Serum C15:0 and C17:0 levels are significantly inversely associated with the odds of prevalent hypertension, suggesting that serum C15:0 and C17:0 levels may serve as potential biomarkers for hypertension monitoring.
十五烷酸(C15:0)和十七烷酸(C17:0)被认为对心血管健康具有保护作用。然而,关于C15:0和C17:0水平与高血压之间关系的研究仍然有限。这项横断面研究旨在调查奇数链脂肪酸(C15:0和C17:0)血清水平与高血压患病率之间的关联。
本研究使用了2011 - 2014年国家健康与营养检查调查(NHANES)的数据。采用多元逻辑回归模型、受限立方样条(RCS)分析、饱和阈值效应分析和交互效应检验来分析血清C15:0和C17:0水平与高血压患病率之间的关系。
本研究共纳入4775名参与者(C15:0分析组)和4718名参与者(C17:0分析组)。两组的高血压患病率分别为46.99%和46.82%。为了改善数据的分布和可比性,主要分析使用总脂肪酸的千分比(C15:0‰和C17:0‰)。在调整了多个混杂因素后,C15:0‰和C17:0‰水平均与高血压患病率显著负相关。在完全调整模型中,C15:0‰和C17:0‰水平的升高与高血压患病率较低相关(C15:0‰:OR = 0.78,95%CI:0.66 - 0.93,P = 0.0063;C17:0‰:OR = 0.77,95%CI:0.64 - 0.93,P = 0.0074)。进一步的受限立方样条分析显示C15:0‰水平与高血压患病率之间存在显著的非线性关系。饱和阈值效应分析表明,当C15:0‰水平低于1.5‰时,与高血压患病率的负相关更强(OR = 0.42,95%CI:0.23 - 0.77,P = 0.0052),而当C15:0‰水平高于1.5‰时,这种关系减弱(OR = 0.89,95%CI:0.74 - 1.07,P = 0.2158)。交互效应检验表明,在C15:0‰水平≥1.5‰的亚组中,年龄改变了C15:0‰水平与高血压患病率之间的关系。在年龄≥65岁的人群中,C15:0‰水平与高血压患病率负相关(OR = 0.54,95%CI:0.36 - 0.79,P = 0.0384),而在年龄<65岁的人群中未观察到显著关联(OR = 0.83,95%CI:0.68 - 1.02,P = 0.1032)。
血清C15:0和C17:0水平与高血压患病率显著负相关,表明血清C15:0和C17:0水平可能作为高血压监测的潜在生物标志物。